Multiple studies have identified a number of molecular biomarkers that are prognostic for DCIS local recurrence rate including the status of HER-2 amplification (23), negative hormone receptor status (24, 25), and immunohistochemical detection of a range of biomarkers, including COX2 (26, 27), Ki67 (27), p16 (26–28), p53 (29, 30), p21 (31), and BNIP3 (32). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.